TiumBio Co., Ltd.

Equities

A321550

KR7321550006

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 22/05/2024 BST			5-day change	1st Jan Change
7,080 ^KRW	-1.80%		+1.29%	-27.53%

05-08	TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain	CI
03-26	Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients	CI

TiumBio Co. Ltd. has completed an IPO in the amount of KRW 30 billion.

November 21, 2019 at 05:00 am

TiumBio Co. Ltd. has completed an IPO in the amount of KRW 30 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 2,500,000 PriceRange: KRW 12000 Transaction Features: Sponsor Backed Offering

Latest news about TiumBio Co., Ltd.

TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain	05-08	CI
Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients	03-26	CI
TiumBio Co., Ltd. Announces to Initiate Phase 2 Trial of TU2218 for Cancer	03-11	CI
TiumBio Co., Ltd. announced that it has received KRW 19.9999947 billion in funding from SK Chemicals Co.,Ltd	12-27	CI
TiumBio Co., Ltd. announced that it expects to receive funding from SK Chemicals Co.,Ltd	12-19	CI
TiumBio Co., Ltd. announced that it has received KRW 18.5 billion in funding from a group of investors	22/10/23	CI
TiumBio Co., Ltd.(KOSDAQ:A321550) dropped from S&P Global BMI Index	18/09/23	CI
TiumBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	21/03/23	CI
Hansoh Pharmaceutical Group Company Limited Announces Licensing Agreement with Tiumbio Co., Ltd	08/08/22	CI
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates	21/10/21	CI
Protium Science announced that it has received KRW 6 billion in funding from TiumBio Co., Ltd.	26/09/21	CI
Protium Science announced that it expects to receive KRW 6 billion in funding from TiumBio Co., Ltd.	14/09/21	CI
TiumBio Co., Ltd. announced that it has received KRW 49.99982815 billion in funding from Hanyang Securities Co. Ltd., EBEST Investment & Securities Co., Ltd. and other investors	02/09/21	CI
TiumBio Co., Ltd. announced that it has received KRW 25 billion in funding	30/08/21	CI
TiumBio Co., Ltd. announced that it expects to receive KRW 49.99982815 billion in funding from Hanyang Securities Co. Ltd., EBEST Investment & Securities Co., Ltd. and other investors	26/08/21	CI
SK Plasma Co., Ltd. announced that it expects to receive KRW 110.00001 billion in funding from SK Discovery Co., Ltd., TiumBio Co., Ltd., and another investor	27/07/21	CI
TiumBio Co., Ltd.(KOSDAQ:A321550) added to S&P Global BMI Index	22/06/20	CI
TiumBio Co. Ltd. has completed an IPO in the amount of KRW 30 billion.	21/11/19	CI
TiumBio Co. Ltd. has filed an IPO.	24/06/19	CI

Chart TiumBio Co., Ltd.

Duration

Period

More charts

Company Profile

TiumBio Co., Ltd. is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company researches and develops small molecule drugs including endometriosis treatments, uterine fibroids treatments, cancer immunotherapy drugs; and new biopharmaceuticals including hemophilia treatments, and others.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TIUMBIO CO., LTD.	-27.53%	137M
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs